| Stereochemistry | RACEMIC |
| Molecular Formula | C15H12O7 |
| Molecular Weight | 304.2516 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H]1[C@H](OC2=C(C1=O)C(O)=CC(O)=C2)C3=CC(O)=C(O)C=C3
InChI
InChIKey=CXQWRCVTCMQVQX-LSDHHAIUSA-N
InChI=1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H/t14-,15+/m0/s1
| Molecular Formula | C15H12O7 |
| Molecular Weight | 304.2516 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Dihydroquercetin (also known as taxifolin) is a flavonoid found in grapes, citrus fruits, onions, green tea, olive oil, and several herbs (such as milk thistle). Besides its antitumor, hepatoprotective, and anti-inflammatory activities, it is a potent antioxidant, which may contribute to its cardiovascular and neuroprotective properties. The drug was tested in vitro against cancer cells and in vivo, in preclinical models of liver diseases and cardiovascular diseases. The possible mechanism of actions involves the induction of phase II detoxifying enzymes and the suppression of cytochrome P450-dependent monooxygenases, apoptosis and disruption of cancer cell cycle progression.
Approval Year
PubMed
Sample Use Guides
In a preclinical study, rats with hepatitis were given 100 mg/kg dihydroquercetin s.c. for 4 days.
Route of Administration:
Other
in a MTT cytotoxicity assay, HCT116 cells (1*10(4) cells per well) were plated onto 96-well plates, incubated at 37C for 24 h, and the cells were treated with various concentrations of dihydroquercetin (3.9-250 uM). After 24 h, 10 ml of CCK-8 solution was added to the wells, and incubation continued for another 3 h.